InsiderTrades.com logo
New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar
From Darwin   |   Ad
As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.
👉 Click here to access your FREE report now!

CDT Insider Trading

Insider Ownership Percentage: 34.74%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $1,447,018.19

Conduit Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Conduit Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Conduit Pharmaceuticals Share Price & Price History

Current Price: $0.09
Price Change: +0.30 (1.20%)
As of 11/20/2024 01:00 AM ET

This chart shows the closing price history over time for CDT up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
My #1 Pre IPO Trade for 2025 – NAME and TICKER
From Wyatt Investment Research   |   Ad
One tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report...
The Next SpaceX Pre-IPO

Conduit Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/7/2024Ltd NirlandMajor ShareholderSell939,009$0.10$93,900.906,092,000View SEC Filing Icon  
10/4/2024Ltd NirlandMajor ShareholderSell1,368,991$0.10$136,899.107,031,009View SEC Filing Icon  
10/2/2024Ltd NirlandMajor ShareholderSell333,177$0.10$33,317.709,900,000View SEC Filing Icon  
9/30/2024Ltd NirlandMajor ShareholderSell1,016,823$0.12$122,018.7611,483,177View SEC Filing Icon  
7/17/2024Andrew ReganDirectorSell1,514,100$0.26$393,666.00177,627View SEC Filing Icon  
7/15/2024Andrew ReganDirectorSell1,005,200$0.25$251,300.0011,936,119View SEC Filing Icon  
7/12/2024Andrew ReganDirectorSell1,389,820$0.25$347,455.0012,941,319View SEC Filing Icon  
7/10/2024Andrew ReganDirectorSell150,000$0.33$49,500.0015,214,091View SEC Filing Icon  
7/8/2024Andrew ReganDirectorSell35,923$0.51$18,320.7315,441,772View SEC Filing Icon  
7/3/2024Andrew ReganDirectorSell1,000$0.64$640.0015,477,695View SEC Filing Icon  
See Full Table
When it comes to NVDA… “acceleration cycles” are the key
From DTI   |   Ad
Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.
Use this link to see Nvidia Unchained right away!

SEC Filings (Institutional Ownership Changes) for Conduit Pharmaceuticals (NASDAQ:CDT)

3.29% of Conduit Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Conduit Pharmaceuticals logo
Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.
Read More on Conduit Pharmaceuticals

Today's Range

Now: $0.09
Low: $0.09
High: $0.10

50 Day Range

MA: $0.11
Low: $0.09
High: $0.14

52 Week Range

Now: $0.09
Low: $0.08
High: $7.83

Volume

4,852,189 shs

Average Volume

6,946,361 shs

Market Capitalization

$8.86 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.14

Who are the company insiders with the largest holdings of Conduit Pharmaceuticals?

Conduit Pharmaceuticals' top insider investors include:
  1. Andrew Regan (Director)
  2. Ltd Nirland (Major Shareholder)
Learn More about top insider investors at Conduit Pharmaceuticals.
New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar
From Darwin   |   Ad
As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.
👉 Click here to access your FREE report now!